Clinical trial
A Study of Lenvatinib in Korean Unresectable Hepatocellular Carcinoma (uHCC) Patients as a Post-marketing Surveillance
NCT05225207 is registered in ClinicalTrials.gov with Eisai Korea Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Study of Lenvatinib in Korean Unresectable Hepatocellular Carcinoma (uHCC) Patients as a Post-marketing Surveillance
- Lead sponsor
- Eisai Korea Inc.
- Phase
- Observational
- Overall status
- Completed
- Start date
- May 28, 2019
- Completion date
- January 31, 2022
- Enrollment
- 658 (actual)
- Sites
- 42
Conditions
As the registry lists them; a condition with its own page is linked.